Table 1.

Methods data of the three published meta-analyses on neo-adjuvant therapy in pancreatic carcinoma n (%)

	Year	n	Type study	Mean age (yr)	Chemotherapy Agents regimen			Radiotherapy Dose (Gy) IORT
Gillen et al[2]	80-09	111	78P-33R	62.5	107 (96.4)	5FU > GEM > Tax > Others	44S + 48C	104 (93.7)	24-63	13 (12.5)
Assifi et al[35]	93-10	14	14P-0R	N/P	14 (100)	GEM > 5FU	3S + 11C	12 (85)	30-50	0 (0)
Andriulli et al[36]	97-08	20	20P-0R	63.0	20 (100)	GEM > Cis	13S + 7C	17 (85)	30-40	N/P

P: Prospective; R: Retrospective; 5FU: 5-fluor-uracil; GEM: Gemcitabine; Cis: Cisplatine; Tax: Taxanes; S: Single; C: Combined; IORT: Intraoperative radiotherapy; N/P: Not provided.